Serum YKL-40 predicts long-term outcome in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction
Serum YKL-40, a potential inflammatory marker, is greatly increased at the early stage of ST-segment elevation myocardial infarction (STEMI). Here, we hypothesized that YKL-40 levels at admission could predict the long-term outcomes after STEMI.A total of 324 patients with acute STEMI undergoing pri...
Gespeichert in:
| Veröffentlicht in: | Medicine (Baltimore) 2019-03, Vol.98 (12), p.e14920-e14920 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e14920 |
|---|---|
| container_issue | 12 |
| container_start_page | e14920 |
| container_title | Medicine (Baltimore) |
| container_volume | 98 |
| creator | Yang, Luyu Dong, Hui Lu, Huizhi Liao, Youxia Zhang, Hao Xu, Lingwen Tan, Yun Cao, Song Tan, Jinhui Fu, Shouzhi |
| description | Serum YKL-40, a potential inflammatory marker, is greatly increased at the early stage of ST-segment elevation myocardial infarction (STEMI). Here, we hypothesized that YKL-40 levels at admission could predict the long-term outcomes after STEMI.A total of 324 patients with acute STEMI undergoing primary percutaneous coronary intervention (PCI) were consecutively enrolled and followed for 24 months. The baseline clinical and procedural data were recorded, and serum YKL-40 levels at admission were measured using ELISA method. The endpoint of interest was major adverse cardiac event (MACE), including all-cause death, recurrent myocardial infarction, and hospitalization for heart failure.Patients with elevated serum YKL-40 levels (≥126.8 ng/mL) were more likely to be older and smoker and to present with type 2 diabetes, advanced Killip class, multivessel disease and intra-aortic balloon pump, with increased levels of admission glucose, triglyceride, and high-sensitivity C-reactive protein and decreased level of high-density lipoprotein cholesterol. During the follow-up period, the incidence of MACE was notably higher in the high than in the low YKL-40 groups (28.4% vs 11.1%, P |
| doi_str_mv | 10.1097/MD.0000000000014920 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6709285</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2195270173</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4508-d4bb03c71533643df210b310d1ad45417e35ff5b3a2a2fd104e2e3a6f9478e963</originalsourceid><addsrcrecordid>eNpdUclu1DAYthCIDoUnQEI-cknxGscXJNSyiak4tBw4WY7zJ2NI7MFOpuqb8Lh4OkNZfLH0bf-G0HNKzijR6tXlxRn586jQjDxAKyp5XUldi4doRQiTldJKnKAnOX8rIq6YeIxOOGl0XQu9Qj-vIC0T_vppXQmCtwk67-aMxxiGaoY04bjMLk6AfcBbO3sIhV1CB2mIPgzF4SebbvEWkltmGyAuGbuYYtijPpSMXfH4GHAfE766rjIMU0EwjLCzd8R0G51NnbdjMfQ2uT36FD3q7Zjh2fE_RV_evb0-_1CtP7__eP5mXTkhSVN1om0Jd6qMzWvBu55R0nJKOmo7IQVVwGXfy5ZbZlnfUSKAAbd1r4VqQNf8FL0-5G6XdoLOldaSHc1xLhOtN_8ywW_MEHemVkSzRpaAl8eAFH8skGcz-exgHA_LMIxqyRShihcpP0hdijkn6O_LUGL2NzWXF-b_mxbXi787vPf8PmIRiIPgJo5l3_n7uNxAMhuw47y5y5NKs4oRqglnjFQF4Q3_BZ2DsOQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2195270173</pqid></control><display><type>article</type><title>Serum YKL-40 predicts long-term outcome in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Wolters Kluwer Open Health</source><source>IngentaConnect Free/Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Yang, Luyu ; Dong, Hui ; Lu, Huizhi ; Liao, Youxia ; Zhang, Hao ; Xu, Lingwen ; Tan, Yun ; Cao, Song ; Tan, Jinhui ; Fu, Shouzhi</creator><creatorcontrib>Yang, Luyu ; Dong, Hui ; Lu, Huizhi ; Liao, Youxia ; Zhang, Hao ; Xu, Lingwen ; Tan, Yun ; Cao, Song ; Tan, Jinhui ; Fu, Shouzhi</creatorcontrib><description>Serum YKL-40, a potential inflammatory marker, is greatly increased at the early stage of ST-segment elevation myocardial infarction (STEMI). Here, we hypothesized that YKL-40 levels at admission could predict the long-term outcomes after STEMI.A total of 324 patients with acute STEMI undergoing primary percutaneous coronary intervention (PCI) were consecutively enrolled and followed for 24 months. The baseline clinical and procedural data were recorded, and serum YKL-40 levels at admission were measured using ELISA method. The endpoint of interest was major adverse cardiac event (MACE), including all-cause death, recurrent myocardial infarction, and hospitalization for heart failure.Patients with elevated serum YKL-40 levels (≥126.8 ng/mL) were more likely to be older and smoker and to present with type 2 diabetes, advanced Killip class, multivessel disease and intra-aortic balloon pump, with increased levels of admission glucose, triglyceride, and high-sensitivity C-reactive protein and decreased level of high-density lipoprotein cholesterol. During the follow-up period, the incidence of MACE was notably higher in the high than in the low YKL-40 groups (28.4% vs 11.1%, P < .001). Kaplan-Meier curve showed that elevated YKL-40 levels were associated with reduced MACE-free survivals (log-rank P < .001). In multivariate Cox regression analysis, we found that high serum YKL-40 level was an independent predictor of MACE after controlling for clinical and angiographic variables (hazard ratio: 1.65, 95% confidence interval: 1.14-2.39, P = .008).The results of our study indicate that serum YKL-40 may be used as a biomarker to predict the long-term outcome after PCI in patients with STEMI.</description><identifier>ISSN: 0025-7974</identifier><identifier>ISSN: 1536-5964</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000014920</identifier><identifier>PMID: 30896649</identifier><language>eng</language><publisher>United States: the Author(s). Published by Wolters Kluwer Health, Inc</publisher><subject>Age Factors ; Aged ; Biomarkers ; Blood Glucose ; C-Reactive Protein - analysis ; Chitinase-3-Like Protein 1 - blood ; Diabetes Mellitus, Type 2 - epidemiology ; Female ; Humans ; Lipids - blood ; Male ; Middle Aged ; Observational Study ; Percutaneous Coronary Intervention - statistics & numerical data ; Prospective Studies ; Severity of Illness Index ; Smoking - epidemiology ; Socioeconomic Factors ; ST Elevation Myocardial Infarction - blood ; ST Elevation Myocardial Infarction - epidemiology ; ST Elevation Myocardial Infarction - surgery</subject><ispartof>Medicine (Baltimore), 2019-03, Vol.98 (12), p.e14920-e14920</ispartof><rights>the Author(s). Published by Wolters Kluwer Health, Inc.</rights><rights>Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4508-d4bb03c71533643df210b310d1ad45417e35ff5b3a2a2fd104e2e3a6f9478e963</citedby><cites>FETCH-LOGICAL-c4508-d4bb03c71533643df210b310d1ad45417e35ff5b3a2a2fd104e2e3a6f9478e963</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709285/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709285/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30896649$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, Luyu</creatorcontrib><creatorcontrib>Dong, Hui</creatorcontrib><creatorcontrib>Lu, Huizhi</creatorcontrib><creatorcontrib>Liao, Youxia</creatorcontrib><creatorcontrib>Zhang, Hao</creatorcontrib><creatorcontrib>Xu, Lingwen</creatorcontrib><creatorcontrib>Tan, Yun</creatorcontrib><creatorcontrib>Cao, Song</creatorcontrib><creatorcontrib>Tan, Jinhui</creatorcontrib><creatorcontrib>Fu, Shouzhi</creatorcontrib><title>Serum YKL-40 predicts long-term outcome in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>Serum YKL-40, a potential inflammatory marker, is greatly increased at the early stage of ST-segment elevation myocardial infarction (STEMI). Here, we hypothesized that YKL-40 levels at admission could predict the long-term outcomes after STEMI.A total of 324 patients with acute STEMI undergoing primary percutaneous coronary intervention (PCI) were consecutively enrolled and followed for 24 months. The baseline clinical and procedural data were recorded, and serum YKL-40 levels at admission were measured using ELISA method. The endpoint of interest was major adverse cardiac event (MACE), including all-cause death, recurrent myocardial infarction, and hospitalization for heart failure.Patients with elevated serum YKL-40 levels (≥126.8 ng/mL) were more likely to be older and smoker and to present with type 2 diabetes, advanced Killip class, multivessel disease and intra-aortic balloon pump, with increased levels of admission glucose, triglyceride, and high-sensitivity C-reactive protein and decreased level of high-density lipoprotein cholesterol. During the follow-up period, the incidence of MACE was notably higher in the high than in the low YKL-40 groups (28.4% vs 11.1%, P < .001). Kaplan-Meier curve showed that elevated YKL-40 levels were associated with reduced MACE-free survivals (log-rank P < .001). In multivariate Cox regression analysis, we found that high serum YKL-40 level was an independent predictor of MACE after controlling for clinical and angiographic variables (hazard ratio: 1.65, 95% confidence interval: 1.14-2.39, P = .008).The results of our study indicate that serum YKL-40 may be used as a biomarker to predict the long-term outcome after PCI in patients with STEMI.</description><subject>Age Factors</subject><subject>Aged</subject><subject>Biomarkers</subject><subject>Blood Glucose</subject><subject>C-Reactive Protein - analysis</subject><subject>Chitinase-3-Like Protein 1 - blood</subject><subject>Diabetes Mellitus, Type 2 - epidemiology</subject><subject>Female</subject><subject>Humans</subject><subject>Lipids - blood</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Observational Study</subject><subject>Percutaneous Coronary Intervention - statistics & numerical data</subject><subject>Prospective Studies</subject><subject>Severity of Illness Index</subject><subject>Smoking - epidemiology</subject><subject>Socioeconomic Factors</subject><subject>ST Elevation Myocardial Infarction - blood</subject><subject>ST Elevation Myocardial Infarction - epidemiology</subject><subject>ST Elevation Myocardial Infarction - surgery</subject><issn>0025-7974</issn><issn>1536-5964</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdUclu1DAYthCIDoUnQEI-cknxGscXJNSyiak4tBw4WY7zJ2NI7MFOpuqb8Lh4OkNZfLH0bf-G0HNKzijR6tXlxRn586jQjDxAKyp5XUldi4doRQiTldJKnKAnOX8rIq6YeIxOOGl0XQu9Qj-vIC0T_vppXQmCtwk67-aMxxiGaoY04bjMLk6AfcBbO3sIhV1CB2mIPgzF4SebbvEWkltmGyAuGbuYYtijPpSMXfH4GHAfE766rjIMU0EwjLCzd8R0G51NnbdjMfQ2uT36FD3q7Zjh2fE_RV_evb0-_1CtP7__eP5mXTkhSVN1om0Jd6qMzWvBu55R0nJKOmo7IQVVwGXfy5ZbZlnfUSKAAbd1r4VqQNf8FL0-5G6XdoLOldaSHc1xLhOtN_8ywW_MEHemVkSzRpaAl8eAFH8skGcz-exgHA_LMIxqyRShihcpP0hdijkn6O_LUGL2NzWXF-b_mxbXi787vPf8PmIRiIPgJo5l3_n7uNxAMhuw47y5y5NKs4oRqglnjFQF4Q3_BZ2DsOQ</recordid><startdate>20190301</startdate><enddate>20190301</enddate><creator>Yang, Luyu</creator><creator>Dong, Hui</creator><creator>Lu, Huizhi</creator><creator>Liao, Youxia</creator><creator>Zhang, Hao</creator><creator>Xu, Lingwen</creator><creator>Tan, Yun</creator><creator>Cao, Song</creator><creator>Tan, Jinhui</creator><creator>Fu, Shouzhi</creator><general>the Author(s). Published by Wolters Kluwer Health, Inc</general><general>Wolters Kluwer Health</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20190301</creationdate><title>Serum YKL-40 predicts long-term outcome in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction</title><author>Yang, Luyu ; Dong, Hui ; Lu, Huizhi ; Liao, Youxia ; Zhang, Hao ; Xu, Lingwen ; Tan, Yun ; Cao, Song ; Tan, Jinhui ; Fu, Shouzhi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4508-d4bb03c71533643df210b310d1ad45417e35ff5b3a2a2fd104e2e3a6f9478e963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Age Factors</topic><topic>Aged</topic><topic>Biomarkers</topic><topic>Blood Glucose</topic><topic>C-Reactive Protein - analysis</topic><topic>Chitinase-3-Like Protein 1 - blood</topic><topic>Diabetes Mellitus, Type 2 - epidemiology</topic><topic>Female</topic><topic>Humans</topic><topic>Lipids - blood</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Observational Study</topic><topic>Percutaneous Coronary Intervention - statistics & numerical data</topic><topic>Prospective Studies</topic><topic>Severity of Illness Index</topic><topic>Smoking - epidemiology</topic><topic>Socioeconomic Factors</topic><topic>ST Elevation Myocardial Infarction - blood</topic><topic>ST Elevation Myocardial Infarction - epidemiology</topic><topic>ST Elevation Myocardial Infarction - surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, Luyu</creatorcontrib><creatorcontrib>Dong, Hui</creatorcontrib><creatorcontrib>Lu, Huizhi</creatorcontrib><creatorcontrib>Liao, Youxia</creatorcontrib><creatorcontrib>Zhang, Hao</creatorcontrib><creatorcontrib>Xu, Lingwen</creatorcontrib><creatorcontrib>Tan, Yun</creatorcontrib><creatorcontrib>Cao, Song</creatorcontrib><creatorcontrib>Tan, Jinhui</creatorcontrib><creatorcontrib>Fu, Shouzhi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, Luyu</au><au>Dong, Hui</au><au>Lu, Huizhi</au><au>Liao, Youxia</au><au>Zhang, Hao</au><au>Xu, Lingwen</au><au>Tan, Yun</au><au>Cao, Song</au><au>Tan, Jinhui</au><au>Fu, Shouzhi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum YKL-40 predicts long-term outcome in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2019-03-01</date><risdate>2019</risdate><volume>98</volume><issue>12</issue><spage>e14920</spage><epage>e14920</epage><pages>e14920-e14920</pages><issn>0025-7974</issn><issn>1536-5964</issn><eissn>1536-5964</eissn><abstract>Serum YKL-40, a potential inflammatory marker, is greatly increased at the early stage of ST-segment elevation myocardial infarction (STEMI). Here, we hypothesized that YKL-40 levels at admission could predict the long-term outcomes after STEMI.A total of 324 patients with acute STEMI undergoing primary percutaneous coronary intervention (PCI) were consecutively enrolled and followed for 24 months. The baseline clinical and procedural data were recorded, and serum YKL-40 levels at admission were measured using ELISA method. The endpoint of interest was major adverse cardiac event (MACE), including all-cause death, recurrent myocardial infarction, and hospitalization for heart failure.Patients with elevated serum YKL-40 levels (≥126.8 ng/mL) were more likely to be older and smoker and to present with type 2 diabetes, advanced Killip class, multivessel disease and intra-aortic balloon pump, with increased levels of admission glucose, triglyceride, and high-sensitivity C-reactive protein and decreased level of high-density lipoprotein cholesterol. During the follow-up period, the incidence of MACE was notably higher in the high than in the low YKL-40 groups (28.4% vs 11.1%, P < .001). Kaplan-Meier curve showed that elevated YKL-40 levels were associated with reduced MACE-free survivals (log-rank P < .001). In multivariate Cox regression analysis, we found that high serum YKL-40 level was an independent predictor of MACE after controlling for clinical and angiographic variables (hazard ratio: 1.65, 95% confidence interval: 1.14-2.39, P = .008).The results of our study indicate that serum YKL-40 may be used as a biomarker to predict the long-term outcome after PCI in patients with STEMI.</abstract><cop>United States</cop><pub>the Author(s). Published by Wolters Kluwer Health, Inc</pub><pmid>30896649</pmid><doi>10.1097/MD.0000000000014920</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0025-7974 |
| ispartof | Medicine (Baltimore), 2019-03, Vol.98 (12), p.e14920-e14920 |
| issn | 0025-7974 1536-5964 1536-5964 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6709285 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Wolters Kluwer Open Health; IngentaConnect Free/Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Age Factors Aged Biomarkers Blood Glucose C-Reactive Protein - analysis Chitinase-3-Like Protein 1 - blood Diabetes Mellitus, Type 2 - epidemiology Female Humans Lipids - blood Male Middle Aged Observational Study Percutaneous Coronary Intervention - statistics & numerical data Prospective Studies Severity of Illness Index Smoking - epidemiology Socioeconomic Factors ST Elevation Myocardial Infarction - blood ST Elevation Myocardial Infarction - epidemiology ST Elevation Myocardial Infarction - surgery |
| title | Serum YKL-40 predicts long-term outcome in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T05%3A07%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20YKL-40%20predicts%20long-term%20outcome%20in%20patients%20undergoing%20primary%20percutaneous%20coronary%20intervention%20for%20ST-segment%20elevation%20myocardial%20infarction&rft.jtitle=Medicine%20(Baltimore)&rft.au=Yang,%20Luyu&rft.date=2019-03-01&rft.volume=98&rft.issue=12&rft.spage=e14920&rft.epage=e14920&rft.pages=e14920-e14920&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000014920&rft_dat=%3Cproquest_pubme%3E2195270173%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2195270173&rft_id=info:pmid/30896649&rfr_iscdi=true |